Boosting anticancer vaccines: Too much of a good thing?

Using both transplantable and oncogene-driven autochthonous tumor models challenged with dendritic cell-based vaccines, we have recently found that boosting provides a clear advantage in prophylactic settings, unless performed on an excessively tight schedule, which causes the loss of central memory...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricupito, Alessia, Grioni, Matteo, Calcinotto, Arianna, Bellone, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782130/
https://www.ncbi.nlm.nih.gov/pubmed/24073378
http://dx.doi.org/10.4161/onci.25032
_version_ 1782285518541684736
author Ricupito, Alessia
Grioni, Matteo
Calcinotto, Arianna
Bellone, Matteo
author_facet Ricupito, Alessia
Grioni, Matteo
Calcinotto, Arianna
Bellone, Matteo
author_sort Ricupito, Alessia
collection PubMed
description Using both transplantable and oncogene-driven autochthonous tumor models challenged with dendritic cell-based vaccines, we have recently found that boosting provides a clear advantage in prophylactic settings, unless performed on an excessively tight schedule, which causes the loss of central memory T cells. In therapeutic settings, boosting turned out to be always detrimental.
format Online
Article
Text
id pubmed-3782130
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-37821302013-09-26 Boosting anticancer vaccines: Too much of a good thing? Ricupito, Alessia Grioni, Matteo Calcinotto, Arianna Bellone, Matteo Oncoimmunology Author's View Using both transplantable and oncogene-driven autochthonous tumor models challenged with dendritic cell-based vaccines, we have recently found that boosting provides a clear advantage in prophylactic settings, unless performed on an excessively tight schedule, which causes the loss of central memory T cells. In therapeutic settings, boosting turned out to be always detrimental. Landes Bioscience 2013-07-01 2013-05-16 /pmc/articles/PMC3782130/ /pubmed/24073378 http://dx.doi.org/10.4161/onci.25032 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Ricupito, Alessia
Grioni, Matteo
Calcinotto, Arianna
Bellone, Matteo
Boosting anticancer vaccines: Too much of a good thing?
title Boosting anticancer vaccines: Too much of a good thing?
title_full Boosting anticancer vaccines: Too much of a good thing?
title_fullStr Boosting anticancer vaccines: Too much of a good thing?
title_full_unstemmed Boosting anticancer vaccines: Too much of a good thing?
title_short Boosting anticancer vaccines: Too much of a good thing?
title_sort boosting anticancer vaccines: too much of a good thing?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782130/
https://www.ncbi.nlm.nih.gov/pubmed/24073378
http://dx.doi.org/10.4161/onci.25032
work_keys_str_mv AT ricupitoalessia boostinganticancervaccinestoomuchofagoodthing
AT grionimatteo boostinganticancervaccinestoomuchofagoodthing
AT calcinottoarianna boostinganticancervaccinestoomuchofagoodthing
AT bellonematteo boostinganticancervaccinestoomuchofagoodthing

Ejemplares similares